PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Somatic mutations affect key pathways in lung adenocarcinoma

Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681

Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN

Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551

Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer

Rikova, K., Guo, A., Zeng, Q., Possemato, A., Yu, J., Haack, H., Nardone, J., Lee, K., Reeves, C., Li, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.11.025 · Cited by 2,317

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Bean, J., Brennan, C., Shih, J.-Y., Riely, G., Viale, A., Wang, L., Chitale, D., Motoi, N., Szoke, J., Broderick, S., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0710370104 · Cited by 1,598

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors

Mellinghoff, I. K., Wang, M. Y., Vivanco, I., Haas-Kogan, D. A., Zhu, S., Dia, E. Q., Lu, K. V., Yoshimoto, K., Huang, J. H. Y., Chute, D. J., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051918 · Cited by 1,442

Characterizing the cancer genome in lung adenocarcinoma

Weir, B. A., Woo, M. S., Getz, G., Perner, S., Ding, L., Beroukhim, R., Lin, W. M., Province, M. A., Kraja, A., Johnson, L. A., et al. (2007) · Nature · doi:10.1038/nature06358 · Cited by 1,105

The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway

Sansal, I., & Sellers, W. R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.02.141 · Cited by 933

Mechanisms of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer

Engelman, J. A., & Janne, P. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-2248 · Cited by 706

Signaling networks assembled by oncogenic EGFR and c-Met

Guo, A., Villén, J., Kornhauser, J. M., Lee, K. A., Stokes, M. P., Rikova, K., Possemato, A. P., Nardone, J., Innocenti, G., Wetzel, R. K., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707270105 · Cited by 511

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

She, Q., Solit, D. B., Ye, Q., O'Reilly, K. E., Lobo, J. M., & Rosen, N. X. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.09.006 · Cited by 416

Metabolic Remodelling: An Accomplice for New Therapeutic Strategies to Fight Lung Cancer

Mendes, C., & Serpa, J. (2019) · Antioxidants · doi:10.3390/antiox8120603 · Cited by 21

Molecularly targeted approaches herald a new era of non-small-cell lung cancer treatment

Okamoto, I., Yoshida, & Kaneda (2013) · Cancer Management and Research · doi:10.2147/cmar.s32973 · Cited by 21

Treating non-small cell lung cancer by targeting the PI3K signaling pathway

Jiang, L., Zhang, J., Xu, Y., Xu, H., & Wang, M. (2022) · Chinese Medical Journal · doi:10.1097/cm9.0000000000002195 · Cited by 23

PTEN and PIK3CA gene copy numbers and poor outcomes in non-small cell lung cancer patients with gefitinib therapy

Fidler, M. J., Morrison, L. E., Basu, S., Buckingham, L. E., Walters, K. S., Batus, M., Jacobson, K., Jewell, S. S., Coon, J., & Bonomi, P. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.494 · Cited by 22

Overcoming Molecular Mechanisms of Resistance to First-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors

Bar, J., & Onn, A. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.001 · Cited by 21

ZNF32 contributes to the induction of multidrug resistance by regulating TGF-β receptor 2 signaling in lung adenocarcinoma

Li, J., Ao, J., Li, K., Zhang, J., Li, Y., Zhang, L., Wei, Y., Gong, D., Gao, J., Tan, W., et al. (2016) · Cell Death and Disease · doi:10.1038/cddis.2016.328 · Cited by 21

Effects of Sunitinib and Other Kinase Inhibitors on Cells Harboring a PDGFRB Mutation Associated with Infantile Myofibromatosis

Šrámek, M., Neradil, J., Macigova, P., Múdry, P., Polášková, K., Slabý, O., Pálová, H., Štěrba, J., & Veselská, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19092599 · Cited by 21

Unraveling the Impact of Intratumoral Heterogeneity on EGFR Tyrosine Kinase Inhibitor Resistance in EGFR-Mutated NSCLC

Kobayashi, K., & Tan, A. C. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24044126 · Cited by 22

Clinical efficacy and identification of factors confer resistance to afatinib (tyrosine kinase inhibitor) in EGFR-overexpressing esophageal squamous cell carcinoma

Wang, Y., Liu, C. X., Chen, H., Jiao, X., Wang, Y., Cao, Y., Li, J., Zhang, X., Sun, Y., Zhuo, N., et al. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01875-4 · Cited by 20

BRAF V600E Is a Determinant of Sensitivity to Proteasome Inhibitors

Zecchin, D., Boscaro, V., Médico, E., Barault, L., Martini, M., Arena, S., Cancelliere, C., Bartolini, A., Crowley, E. H., Bardelli, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0243 · Cited by 21

EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs

Lin, C.-A., Yu, S., Chen, H., Chen, H., Lin, S.-U., Chang, C., Yu, C., Yang, P., & Ho, C. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.11.021 · Cited by 20

KLHL38 involvement in non-small cell lung cancer progression via activation of the Akt signaling pathway

Xu, Y., Wang, C., Jiang, X., Zhang, Y., Su, H., Jiang, J., Ren, H., & Qiu, X. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03835-0 · Cited by 18

MLH1V384D polymorphism associates with poor response to EGFR tyrosine kinase inhibitors in patients withEGFRL858R-positive lung adenocarcinoma

Chiu, C., Ho, H., Doong, H., Yeh, Y., Chen, M., Chou, T., & Tsai, C. (2015) · Oncotarget · doi:10.18632/oncotarget.3511 · Cited by 19

Blockade of the ERK pathway enhances the therapeutic efficacy of the histone deacetylase inhibitor MS-275 in human tumor xenograft models

Sakamoto, T., Ozaki, K., Fujio, K., Kajikawa, S., Uesato, S., Watanabe, K., Tanimura, S., Koji, T., & Kohno, M. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.009 · Cited by 19

Four generations of EGFR TKIs associated with different pathogenic mutations in non-small cell lung carcinoma

Li, R., Zhou, X., Yao, H.-J., & Li, L. (2020) · Journal of drug targeting · doi:10.1080/1061186x.2020.1737934 · Cited by 19

PTEN, ATM, IDH1 mutations and MAPK pathway activation as modulators of PFS and OS in patients treated by first line EGFR TKI, an ancillary study of the French Cooperative Thoracic Intergroup (IFCT) Biomarkers France project

Blons, H., Oudart, J.-B., Merlio, J., Debieuvre, D., de Fraipont, F., Audigier-Valette, C., Escande, F., Hominal, S., Bringuier, P., Fraboulet, S. M., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.11.008 · Cited by 19

Correlation between EML4-ALK, EGFR and clinicopathological features based on IASLC/ATS/ERS classification of lung adenocarcinoma

Wang, H., Zhang, W., Wang, K., & Li, X. (2018) · Medicine · doi:10.1097/md.0000000000011116 · Cited by 19

Somatic mutation analysis of KRAS, BRAF, HER2 and PTEN in EGFR mutation-negative non-small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel deletion in HER2 gene from Indian patients

Bhaumik, S., Ahmad, F., & Das, B. R. (2016) · Medical Oncology · doi:10.1007/s12032-016-0828-7 · Cited by 18

Combinatory use of distinct single-cell RNA-seq analytical platforms reveals the heterogeneous transcriptome response

Kashima, Y., Suzuki, A., Liu, Y., Hosokawa, M., Matsunaga, H., Shirai, M., Arikawa, K., Sugano, S., Kohno, T., Takeyama, H., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-21161-y · Cited by 18

Quantifying the sensitivities of EGF receptor (EGFR) tyrosine kinase inhibitors in drug resistant non-small cell lung cancer (NSCLC) cells using hydrogel-based peptide array

Ghosh, G., Yan, X., Lee, A. G., Kron, S. J., & Palecek, S. P. (2010) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2010.07.106 · Cited by 18

Targeting Genomic Alterations in Squamous Cell Lung Cancer

Mantripragada, K. C., & Khurshid, H. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00195 · Cited by 18

Whole genome sequencing of glioblastoma multiforme identifies multiple structural variations involved in EGFR activation

Furgason, J. M., Li, W., Milholland, B., Cross, E., Li, Y., McPherson, C. M., Warnick, R. E., Rixe, O., Stambrook, P. J., Vijg, J., et al. (2014) · Mutagenesis · doi:10.1093/mutage/geu026 · Cited by 16

Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer

Vyse, S., Howitt, A., & Huang, P. H. (2017) · Journal of Molecular Biology · doi:10.1016/j.jmb.2017.04.018 · Cited by 16

The irreversible pan-HER inhibitor PF00299804 alone or combined with gemcitabine has an antitumor effect in biliary tract cancer cell lines

Nam, H.-J., Kim, H.-P., Yoon, Y., Song, S. H., Min, A.-R., Han, S., Im, S., Kim, T. Y., Oh, D. Y., & Bang, Y. J. (2011) · Investigational New Drugs · doi:10.1007/s10637-011-9782-6 · Cited by 17

A Closer Look at EGFR Inhibitor Resistance in Non-Small Cell Lung Cancer through the Lens of Precision Medicine

Sattler, M., Mambetsariev, I., Fricke, J., Tan, T., Liu, S., Vaidehi, N., Pisick, E. P., Mirzapoiazova, T., Rock, A. G., Merla, A., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051936 · Cited by 16

Concomitant EGFR Inhibitors Combined with Radiation for Treatment of Non-small Cell Lung Carcinoma

Zheng, D., Yu, G., Gao, J., & Gu, J.-D. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.8.4485 · Cited by 16

Strategies to Overcome Acquired Resistances Conferred by Mutations in the Kinase Domain of Egfr

Lim, S. M., Jeong, Y., & Hong, S. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0019 · Cited by 16

Inhibiting Pathways Predicted From a Steroid Hormone Gene Signature Yields Synergistic Antitumor Effects in NSCLC

Almotlak, A. A., Farooqui, M., & Siegfried, J. M. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.195 · Cited by 16

Characterizing the malignancy and drug resistance of cancer cells from their membrane resealing response

Hui, T. H., Zhou, Z. L., Fong, A. H.-W., Ngan, R. K. C., Lee, T. Y., Au, J. S. K., Ngan, A. H. W., Yip, T. T. C., & Lin, Y. (2016) · Scientific Reports · doi:10.1038/srep26692 · Cited by 16

PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non–small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors

Ferrara, M. G., Martini, M., D’Argento, E., Forcella, C., Vita, E., Noia, V. D., Sperduti, I., Bilotta, M., Ribelli, M., Damiano, P., et al. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.12.008 · Cited by 16

The Role of Molecular Diagnostics in Cancer Diagnosis and Treatment

Ozretić, L., Heukamp, L. C., Odenthal, M., & Buettner, R. (2012) · Onkologie · doi:10.1159/000334823 · Cited by 16

Emerging drugs for EGFR-mutated non-small cell lung cancer

Sukrithan, V., Deng, L., Barbaro, A., & Cheng, H. (2018) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2018.1558203 · Cited by 16

Implication of mTOR Signaling in NSCLC: Mechanisms and Therapeutic Perspectives

Gargalionis, A. N., Papavassiliou, K. A., & Papavassiliou, A. G. (2023) · Cells · doi:10.3390/cells12152014 · Cited by 15

Host-Dependent Phenotypic Resistance to EGFR Tyrosine Kinase Inhibitors

Haga, Y., Marrocco, I., Noronha, A., Uribe, M. L., Nataraj, N. B., Sekar, A., Garcia, D. D., Borgoni, S., Lindzen, M., Giri, S., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3555 · Cited by 16

Calcium/calmodulin-dependent protein kinase kinase 2 mediates pleiotropic effects of epidermal growth factor in cancer cells

Dai, S., Venturini, E., Yadav, S., Lin, X., Clapp, D., Steckiewicz, M., Gocher, A. M., Hardie, D. G., & Edelman, A. M. (2022) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2022.119252 · Cited by 15

PTEN deficiency confers colorectal cancer cell resistance to dual inhibitors of FLT3 and aurora kinase A

Liu, Y., Yang, E. J., Zhang, B., Miao, Z., Wu, C., Lyu, J., Tan, K., Poon, T. C. W., & Shim, J. S. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.08.011 · Cited by 15

Potential predictive value of serum targeted metabolites and concurrently mutated genes for EGFR-TKI therapeutic efficacy in lung adenocarcinoma patients with EGFR sensitizing mutations.

Han, X., Luo, R., Wang, L., Zhang, L., Wang, T., Zhao, Y., Xiao, S., Qiao, N., Xu, C., Ding, L., et al. (2020) · PubMed Central · Cited by 15

Recent Developments in Tyrosine Kinase Inhibitor-based Nanotherapeutics for EGFR-resistant Non-small Cell Lung Cancer

Kole, E. B., Jadhav, K., Singh, R., Mandpe, S. R., Abhang, A., Verma, R. K., & Naik, J. (2024) · Current Drug Delivery · doi:10.2174/0115672018278617231207051907 · Cited by 14

Somatic Copy Number Alterations at Oncogenic Loci Show Diverse Correlations with Gene Expression

Roszik, J., Wu, C., Siroy, A. E., Lazar, A. J., Davies, M. A., Woodman, S. E., & Kwong, L. N. (2016) · Scientific Reports · doi:10.1038/srep19649 · Cited by 14

Acetyltanshinone IIA reduces the synthesis of cell cycle-related proteins by degrading p70S6K and subsequently inhibits drug-resistant lung cancer cell growth

Huang, B., Hao, M., Li, C., & Luo, K. Q. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106209 · Cited by 13

Phenolic diterpenes from Rosemary supercritical extract inhibit non-small cell lung cancer lipid metabolism and synergise with therapeutic drugs in the clinic

Bouzas, A., de Cedrón, M. G., Colmenarejo, G., Laparra, J. M., Moreno‐Rubio, J., Montoya, J. J., Reglero, G., Casado, E., Tabarés, B., Sereno, M., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1046369 · Cited by 14

Resistance to Therapy

Rivera, G. A., & Wakelee, H. A. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40389-2_9 · Cited by 14

Promoted delivery of salinomycin sodium to lung cancer cells by dual targeting PLGA hybrid nanoparticles

Zhou, J., Sun, J., Chen, H., & Peng, Q. (2018) · International Journal of Oncology · doi:10.3892/ijo.2018.4474 · Cited by 14

Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitors

Tiedt, R., King, F. J., Stamm, C., Niederst, M. J., Delach, S. M., Zumstein-Mecker, S., Meltzer, J., Mulford, I. J., Labrot, E., Engstler, B. S., et al. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112297 · Cited by 13

Synthesis, molecular docking study, and evaluation of the antiproliferative action of a new group of propargylthio- and propargylselenoquinolines

Marciniec, K., Latocha, M. T., Boryczka, S., & Kurczab, R. (2014) · Medicinal Chemistry Research · doi:10.1007/s00044-014-0922-3 · Cited by 13

Combined inhibition of rho-associated protein kinase and EGFR suppresses the invasive phenotype in EGFR-dependent lung cancer cells

Umelo, I. A., Wever, O. D., Kronenberger, P., Noor, A., Teugels, E., Chen, G., Bracke, M., & Grève, J. D. (2015) · Lung Cancer · doi:10.1016/j.lungcan.2015.08.008 · Cited by 13

The Root Extract of Peucedanum praeruptorum Dunn Exerts Anticancer Effects in Human Non-Small-Cell Lung Cancer Cells with Different EGFR Mutation Statuses by Suppressing MET Activity

Park, H.-J., Jeong, J.-H., & Park, S. (2022) · Molecules · doi:10.3390/molecules27072360 · Cited by 13

Comparison of EGFR-TKI and chemotherapy in the first-line treatment of advanced EGFR mutation-positive NSCLC

Fiala, O., Pešek, M., Fínek, J., Benešová, L., Bortlíček, Z., & Minárik, M. (2013) · Neoplasma · doi:10.4149/neo_2013_055 · Cited by 13

miRNAs and resistance to EGFR—TKIs in EGFR-mutant non-small cell lung cancer: beyond ‘traditional mechanisms’ of resistance

Ricciuti, B. (2015) · ecancermedicalscience · doi:10.3332/ecancer.2015.569 · Cited by 13

The Adenovirus-Mediated Transfer ofPTENInhibits the Growth of Esophageal Cancer Cellsin Vitroandin Vivo

Zhou, Y., Zhang, T., Zhao, J., Wang, X., Jiang, T., Gu, Z., Wang, X., & Li, X. (2010) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.90787 · Cited by 14

mTOR Signaling in Glioblastoma: Lessons Learned from Bench to Bedside

Akhavan, D., & Mischel, P. S. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-271-1_5 · Cited by 13

Next‐generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non‐small cell lung cancer

Zhang, Y., Xiong, L., Xie, F., Zheng, X., Li, Y., Zhu, L., & Sun, J. (2021) · Cancer Medicine · doi:10.1002/cam4.3948 · Cited by 12

PTEN deletion drives acute myeloid leukemia resistance to MEK inhibitors

Smith, A. M., Zhang, C. R., Cristino, A. S., Grady, J. P., Fink, J. L., & Moore, A. S. (2019) · Oncotarget · doi:10.18632/oncotarget.27206 · Cited by 12

Gefitinib promotes CXCR4-dependent epithelial to mesenchymal transition via TGF-β1 signaling pathway in lung cancer cells harboring EGFR mutation

Zhu, Q., Zhang, Z., Lu, C., Xu, F., Mao, W., Zhang, K., Shou, H., Liu, Z., Gu, J., & Ge, D. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02266-w · Cited by 12

Identification of Intrinsic Drug Resistance and Its Biomarkers in High-Throughput Pharmacogenomic and CRISPR Screens

Ayestaran, I., Galhoz, A., Spiegel, E., Sidders, B. S., Dry, J. R., Dondelinger, F., Bender, A., McDermott, U., Iorio, F., & Menden, M. P. (2020) · Patterns · doi:10.1016/j.patter.2020.100065 · Cited by 12

Audit of Molecular Mechanisms of Primary and Secondary Resistance to Various Generations of Tyrosine Kinase Inhibitors in Known Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Cancer Patients in a Tertiary Centre

Suryavanshi, M., Jaipuria, J., Mattoo, S., Dhandha, S., & Khatri, M. (2022) · Clinical Oncology · doi:10.1016/j.clon.2022.06.003 · Cited by 13

Opportunities and Challenges of Small Molecule Inhibitors in Glioblastoma Treatment: Lessons Learned from Clinical Trials

Hoosemans, L., Vooijs, M., & Hoeben, A. (2024) · Cancers · doi:10.3390/cancers16173021 · Cited by 13

Combined Treatment with JFKD and Gefitinib Overcomes Drug Resistance in Non-Small Cell Lung Cancer

Huang, X., Jing-chun, S., & Sun, J. (2020) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201021999200819105209 · Cited by 11

In Vivo Anticancer Evaluation of 6b, a Non-Covalent Imidazo[1,2-a]quinoxaline-Based Epidermal Growth Factor Receptor Inhibitor against Human Xenograft Tumor in Nude Mice

Rafiq, Z., Kumar, M., Sharma, N., Yadav, U. P., Singh, T., Joshi, G., Pujala, B., Raja, M., Chatterjee, J., Tikoo, K., et al. (2022) · Molecules · doi:10.3390/molecules27175540 · Cited by 11

Diarylheptanoid 35d overcomes EGFR TKI resistance by inducing hsp70-mediated lysosomal degradation of EGFR in EGFR-mutant lung adenocarcinoma

Hong, X., Hsieh, M., Tseng, T.-Y., Lin, H., Chang, H., Yau, S.-T., Cheng, W., Ke, B., Liao, H.-H., Wu, C., et al. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.104814 · Cited by 11

Biomarker analysis of the phase 3 TORCH trial for first line erlotinib versus chemotherapy in advanced non-small cell lung cancer patients

Kim, L., Saieg, M. A., Maïo, M. D., Gallo, C., Butts, C. A., Ciardiello, F., Feld, R. D., Cheng, D., Gebbia, V., Burgio, M. A., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.15725 · Cited by 11

Whole-exome sequencing identifies key mutated genes in T790M wildtype/cMET-unamplified lung adenocarcinoma with acquired resistance to first-generation EGFR tyrosine kinase inhibitors

Li, C., Liu, H., Zhang, B., Gong, L., Su, Y., Zhang, Z., & Wang, C. (2018) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-018-2634-4 · Cited by 11

An Overview, Current Challenges of Drug Resistance, and Targeting Metastasis Associated With Lung Cancer

Thakur, C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-815720-6.00002-2 · Cited by 13

Precision Oncology: Three Small Steps Forward

Wise, H. C., & Solit, D. B. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.05.009 · Cited by 11

DNA Polymerase Alpha Subunit B Is a Binding Protein for Erlotinib Resistance in Non-Small Cell Lung Cancer

Kim, T. Y., Ji, E. S., Lee, J. Y., Kim, J. Y., Yoo, J. S., Szász, A. M., Döme, B., Marko‐Varga, G., & Kwon, H. J. (2020) · Cancers · doi:10.3390/cancers12092613 · Cited by 11

Elevating CDCA3 Levels Enhances Tyrosine Kinase Inhibitor Sensitivity in TKI-Resistant EGFR Mutant Non-Small-Cell Lung Cancer

Sahin, K. B., Shah, E. T., Ferguson, G. P., Molloy, C., Croft, P. K., Hayes, S. A., Hudson, A. L., Colvin, E. K., Kamitakahara, H., Harvie, R. M., et al. (2021) · Cancers · doi:10.3390/cancers13184651 · Cited by 11

Synthesis and biological evaluation of 7-substituted-1-(3-bromophenylamino)isoquinoline-4-carbonitriles as inhibitors of myosin light chain kinase and epidermal growth factor receptor

Rode, H. B., Sos, M. L., Grütter, C., Heynck, S., Simard, J. R., & Rauh, D. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.11.007 · Cited by 11

Novel targeted therapies in head and neck cancer

Ferreira, M. B. A., Lima, J. P. D. S. N., & Cohen, E. E. W. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.651455 · Cited by 11

In- and ex-vivo molecular imaging of apoptosis to assess sensitivity of non-small cell lung cancer to EGFR inhibitors using probe-based confocal laser endomicroscopy

Guisier, F., Bohn, P., Patout, M., Piton, N., Farah, I., Véra, P., Thiberville, L., & Salaün, M. (2017) · PLoS ONE · doi:10.1371/journal.pone.0180576 · Cited by 11

Integrated genomic approaches identify upregulation of SCRN1 as a novel mechanism associated with acquired resistance to erlotinib in PC9 cells harboring oncogenic EGFR mutation

Kim, N., Cho, A., Watanabe, H., Choi, Y., Aziz, M., Kassner, M., Joung, J., Park, A. K.-J., Francis, J. M., Bae, J. S., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7318 · Cited by 10

Multiple primary lung cancer displaying different EGFR and PTEN molecular profiles

Zhu, Z., Yu, T., & Chai, Y. (2016) · Oncotarget · doi:10.18632/oncotarget.13046 · Cited by 10

Proteogenomic systems analysis identifies targeted therapy resistance mechanisms in EGFR‐mutated lung cancer

Treue, D., Bockmayr, M. L., Stenzinger, A., Heim, D., Hester, S. S., & Klauschen, F. (2018) · International Journal of Cancer · doi:10.1002/ijc.31845 · Cited by 10

Epidermal Growth Factor Receptor Inhibitors: Current Status and Future Directions

Chen, H. X., Cleck, J. N., Coelho, R. P., & Dancey, J. E. (2009) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2009.10.002 · Cited by 10

EGFR Mutant Lung Cancer

Gong, Y., & Pao, W. J. (2011) · Current topics in microbiology and immunology · doi:10.1007/82_2011_171 · Cited by 10

ENDOLUNG trial, part II. A phase II study of the Akt/mTOR inhibitor and autophagy inducer ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with squamous non-small cell lung cancer

Bosch‐Barrera, J., Estévez-García, P., Martín-Martorell, P., Sabatier, R., Nadal, E., Sais, È., Gascón, P., Oaknin, A., Rodon, J. A., Lizcano, J. M., et al. (2025) · Lung Cancer · doi:10.1016/j.lungcan.2025.108105 · Cited by 9

IGF-1R Inhibitors in Cancer: A Review of Available Evidence and Future Outlook

Guven, D., Ahmed, J., Stephen, B., & Naing, A. (2025) · Critical reviews in oncology/hematology · doi:10.1016/j.critrevonc.2025.104809 · Cited by 10

Molecular markers of response and resistance to EGFR inhibitors in head and neck cancers

Eccles, S. A. (2012) · Frontiers in bioscience · doi:10.2741/4118 · Cited by 9

Lung Cancer Genomics in the Era of Accelerated Targeted Drug Development

Wijesinghe, P., & Bollig-Fischer, A. B. (2015) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-24932-2_1 · Cited by 9

Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling

Cui, J., Song, Y., Han, X., Hu, J., Chen, Y., Chen, X., Xu, X., Xing, Y., Lu, H., & Cai, L. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.542007 · Cited by 9

Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance

Kong, X., Wang, Q., Li, J., Li, M., Deng, F., & Li, C. (2022) · European Journal of Histochemistry · doi:10.4081/ejh.2022.3315 · Cited by 9

A real-world study and network pharmacology analysis of EGFR-TKIs combined with ZLJT to delay drug resistance in advanced lung adenocarcinoma

Han, X., Liang, L., He, C., Ren, Q., Su, J., Cao, L., & Zheng, J. (2023) · BMC Complementary Medicine and Therapies · doi:10.1186/s12906-023-04213-3 · Cited by 12

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade

Umelo, I. A., Wever, O. D., Kronenberger, P., Deun, J. V., Noor, A., Singh, K., Teugels, E., Chen, G., Bracke, M., & Grève, J. D. (2015) · Oncotarget · doi:10.18632/oncotarget.3853 · Cited by 9

Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation

Isobe, K., Kakimoto, A., MIKAMI, T., Kaburaki, K., Kobayashi, H., YOSHIZAWA, T., MAKINO, T., OTSUKA, H., Sano, G., Sugino, K., et al. (2016) · Cancer Genomics & Proteomics · doi:10.21873/cgp.20010 · Cited by 9

Individual Biomarkers Using Molecular Personalized Medicine Approaches

Zenner, H. P. (2017) · ORL · doi:10.1159/000455811 · Cited by 9

Reduced expression levels of PTEN are associated with decreased sensitivity of HCC827 cells to icotinib

Zhai, Y., Zhang, Y., Nan, K., & Liang, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.5829 · Cited by 9

PLCγ1‑dependent invasion and migration of cells expressing NSCLC‑associated EGFR mutants

Mittal, S., Kamath, A., Joseph, A., & Rajala, M. S. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5112 · Cited by 9

Survival‑associated factors of first‑line EGFR‑tyrosine kinase inhibitor responders and non‑responders in lung adenocarcinoma patients with common EGFR mutations

Hung, M., Fang, Y., Lin, Y., Lung, J., Hsieh, M., & Tsai, Y. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1550 · Cited by 9

Small activating ribonucleic acid reverses tyrosine kinase inhibitor resistance in epidermal growth factor receptor‐mutant lung cancer by increasing the expression of phosphatase and tensin homolog

Li, M., Peng, Z., Ren, W., & Wang, Z. (2016) · Thoracic Cancer · doi:10.1111/1759-7714.12356 · Cited by 8

Suberoylanilide hydroxamic acid overcomes erlotinib-acquired resistance via phosphatase and tensin homolog deleted on chromosome 10-mediated apoptosis in non-small cell lung cancer

Wu, P.-F., Gao, W., Sun, C., Ma, T., & Hao, J. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000823 · Cited by 8

Transglutaminase 2 Induces Intrinsic EGFR-TKI Resistance in NSCLC Harboring EGFR Sensitive MutationsPreprint

Choi, J., Yoon, S., Kim, D., Moon, Y. W., Lee, C. H., Seo, S., Cheon, J., Gho, Y. S., Kim, C., Lee, E. R., et al. (2019) · SSRN Electronic Journal · doi:10.2139/ssrn.3379807 · Cited by 8

DUSP22 inhibits lung tumorigenesis by suppression of EGFR/c-Met signaling

Lin, H.-H., Chang, C., Liao, Y., Yeh, S., Lin, H.-P. P., Ho, H., Cheung, C. H. Y., Juan, H., Chen, Y., Su, Y., et al. (2024) · Cell Death Discovery · doi:10.1038/s41420-024-02038-8 · Cited by 8

Tanreqing injection inhibits stemness and enhances sensitivity of non-small cell lung cancer models to gefitinib through ROS/STAT3 signaling pathway

Xiao, Z., Ding, L., Yu, Y., Ma, C., Lei, C., Liu, Y., Chang, X., Chen, Y., He, Y., Zhu, Y.-J., et al. (2024) · Journal of Cancer · doi:10.7150/jca.94438 · Cited by 7

CRISPR knockout screens reveal JUN as the master mediator of resistance to MAPK inhibition in KRAS-mutant pancreatic cancer

Mulero‐Sánchez, A., Bosma, A. R., Visuvasam, B., Pouliopoulou, N., van de Ven, M., Proost, N., Boeije, M., Lieftink, C., Beijersbergen, R. L., Bernards, R., et al. (2026) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-025-03616-z · Cited by 7

Quinalizarin, a specific CK2 inhibitor, can reduce icotinib resistance in human lung adenocarcinoma cell lines

Li, K., Zhou, F., Zhou, Y., Zhang, S., Li, Q., Li, Z., Liu, L., Wu, G., & Meng, R. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4220 · Cited by 7

Putative mechanisms of primary resistance to EGFR-targeted therapies: A retrospective study

Tu, X., Lu, Z., Hei, F., Zhang, T., Wang, X. M., Chen, D., Fan, F., Xu, J., Zhang, X., & Guo, K. (2024) · Lung Cancer · doi:10.1016/j.lungcan.2024.107998 · Cited by 6

Sensitivity and resistance to EGF-R inhibitors

Peipp, M., Dechant, M., & Valerius, T. (2009) · mAbs · doi:10.4161/mabs.1.6.10051 · Cited by 6

Reduced expression of CYLD promotes cell survival and inflammation in gefitinib‐treated NSCLC PC‐9 cells: Targeting CYLD may be beneficial for acquired resistance to gefitinib therapy

Yuan, Y., Liu, L., Wang, Y., & Liu, S. (2020) · Cell Biology International · doi:10.1002/cbin.11397 · Cited by 6

Development of personalized treatments in lung cancer: focusing on the EGFR mutations and beyond

Mitsudomi, T., & Suda, K. (2013) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s49603 · Cited by 6

HIV Integration into the PTEN Gene and Its Tumor Microenvironment Implications for Lung Cancer

Smith, D. M., Rowland, E. F., Gianella, S., Patel, S. P., Solso, S., Dullano, C., Deiss, R., Wells, D., Ignacio, C. C., Caballero, G., et al. (2025) · Current Oncology · doi:10.3390/curroncol32070389 · Cited by 5

Effects of Thymoquinone on Cell Proliferation, Oxidative Damage, and Toll-like Signaling Pathway Genes in H1650 Lung Adenocarcinoma Cell Line

Karaoğlanoğlu, S., & Gülbay, G. (2025) · Medicina · doi:10.3390/medicina61101835 · Cited by 5

Editor’s Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR

Sos, M. L., Koker, M., Weir, B. A., Heynck, S., Rabinovsky, R., Zander, T., Seeger, J. M., Weiss, J. M., Fischer, F., Frommolt, P., et al. (2025) · Cancer Research · doi:10.1158/0008-5472.can-24-5044

Novel two mechanisms for acquired EGFR-TKI resistance in lung cancer cells harboring EGFR activating mutation

Izumi, H., Kanda, R., Murakami, Y., Morimoto, Y., & Ono, M. (2014) · European Respiratory Journal · doi:10.1183/13993003/erj.44.suppl_58.p508 · Cited by 1

Loss of PTEN expression by blocking nuclear translocation of EGR1 in gefitinib-resistant lung cancer cells harboring epidermal growth factor receptor-activating mutations

Yamamoto, C., Basaki, Y., Kawahara, A., Nakashima, K., Kage, M., Izumi, H., Kohno, K., Uramoto, H., Yasumoto, K., Kuwano, M., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0043 · Cited by 155

[Molecular mechanism of erlotinib resistance in epidermal growth factor receptor mutant non-small cell lung cancer cell line H1650].

Han, R., Wang, X., Zhong, D., Zhao, J., Chen, Z., Sun, L., Wang, J., & Zhang, J. (2012) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2012.12.02 · Cited by 2

Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells

Tabara, K., Kanda, R., Sonoda, K., Kubo, T., Murakami, Y., Kawahara, A., Azuma, K., Abe, H., Kage, M., Yoshinaga, A., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0041017 · Cited by 70